US2021002665A1PendingUtilityA1
Rna-guided gene editing and gene regulation
Est. expiryJun 5, 2033(~6.9 yrs left)· nominal 20-yr term from priority
Inventors:Charles A. GersbachIsaac HiltonPablo Perez-PineraAmi M. KabadiPratiksha I. ThakoreDavid G. OusteroutJoshua B. Black
C12N 15/62C12N 15/113C07K 2319/00C12Y 301/00A61K 38/465C12N 2800/40A61K 48/005C07K 2319/71C07K 14/4708C12N 15/85C12N 9/96C12N 2840/20A61K 48/0058C12N 2740/16043C12N 15/907C12N 9/22C12N 9/1007C12N 15/86C12N 2310/20C12N 2750/14143
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based system related compositions and methods of using said CRISPR/Cas9-based system related compositions for altering gene expression and genome engineering. Also disclosed herein are compositions and methods of using said compositions for altering gene expression and genome engineering in muscle, such as skeletal muscle and cardiac muscle.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A DNA targeting system for deleting exon 51 of a dystrophin gene, the system comprising Cas9 and at least one guide RNA (gRNA), wherein the at least one gRNA binds and targets a polynucleotide sequence comprising SEQ ID NO: 67, SEQ ID NO: 70, SEQ ID NO: 100, or SEQ ID NO: 680.
2 . An isolated polynucleotide encoding the DNA targeting system of claim 1 .
3 . A vector comprising the isolated polynucleotide of claim 2 .
4 . A cell comprising the isolated polynucleotide of claim 2 .
5 . A method of treating a subject in need thereof having a mutant dystrophin gene, the method comprising administering to the subject the DNA targeting system of claim 1 .
6 . The method of claim 5 , wherein the subject is suffering from Duchenne muscular dystrophy.
7 . A method of correcting a mutant dystrophin gene in a cell, the method comprising administering to a cell containing a mutant dystrophin gene the DNA targeting system of claim 1 .
8 . A composition for genome editing in a muscle of a subject, the composition comprising a modified adeno-associated virus (AAV) vector and a nucleotide sequence encoding the DNA targeting system of claim 1 , wherein the muscle is skeletal muscle or cardiac muscle.
9 . The composition of claim 8 , wherein the modified AAV vector has enhanced cardiac and skeletal muscle tissue tropism.Join the waitlist — get patent alerts
Track US2021002665A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.